Accenture has invested in Ryght AI, a platform provider that modernizes how clinical research is designed and executed for the life sciences industry. This investment, made through Accenture Ventures, will enable life sciences and clinical research companies to bring new treatments to patients faster by combining agentic AI with enterprise technology solutions.
The clinical trial process is becoming increasingly complex, leading to major delays, especially with site selection and patient enrollment. As the cost of developing new drugs continues to rise, manual site selection can add weeks or months to each study, creating significant bottlenecks that slow down the entire development process and stall the introduction of many promising therapies.
Ryght AI addresses these challenges through its AI Site Twin platform, which creates dynamic digital replicas of clinical research sites, capturing historical performance, patient demographics and operational data in real-time. These tools allow sponsors and contract research organizations to more easily identify the sites that best meet regulations and protocols, forecast enrollment more accurately and streamline site activation workflows.
Also Read: Nona Biosciences Names Dr. Hongjiang Miao Chief AI Officer for A³ Strategy
This investment and collaboration will combine Accenture’s deep industry, technology and data-engineering expertise with Ryght AI’s advanced domain-specific agentic AI platform to help life sciences companies accelerate the three most crucial steps in drug development trial feasibility, site selection and patient recruitment.
“Generative and agentic AI are transforming the foundation of clinical research,” said Petra Jantzer, PhD, a senior managing director and global lead of Life Sciences, Accenture. “With our investment in Ryght AI, we’re giving our life sciences clients the ability to fully leverage operational and scientific data and bring life-changing therapies to market faster, more efficiently and with greater precision.”
“This partnership allows Ryght AI to extend the impact and adoption of our technology to a global scale. Together, we can help life science companies reimagine how clinical trials are planned, launched and managed accelerating the journey from discovery to treatment,” said Simon Arkell, CEO, Ryght AI.
Source: Accenture
